Table 2.
Active, recruiting and completed clinical trials using transposon-mediated gene transfer, May 2020.
| Disease | Clinical Trial ID/Alias | Location | Population Studied; Phase | Transgene | Vector | Status | Reference |
|---|---|---|---|---|---|---|---|
| B-cell lymphoma | NCT00968760 | MDACC 8 (Texas, USA) | Adult; Phase 1 | Autologous anti-CD19.CD28.z CAR T-cells | SB | Active, not recruiting | [30] |
| CD19+ lymphoma, B-ALL 1 | NCT01497184 | MDACC | Children and adult; Phase 1 | Allogeneic anti-CD19.CD28.z CAR T-cells | SB | Active, not recruiting | [30] |
| CD19+ lymphoma,B-ALL | NCT01492036 | MDACC | Children and adult; Phase 1 | Long-term follow-up | SB | Recruiting | [81] |
| B-CLL 2 | NCT01653717 | MDACC | Adult; Phase 1 | Allogeneic anti-CD19.CD28.z CAR T-cells | SB | Completed | |
| CD19+ lymphoma, B-ALL, B-CLL | NCT02529813 | MDACC | Children and adult; Phase 1 | Autologous anti-CD19.CD28.z CAR T-cells | SB | Active, not recruiting | [82] |
| B-ALL | NCT03389035 | MBBM 9/PGXXIII 10 | Children and adult; Phase 1 and 2 | Allogeneic anti-CD19.CD28.OX40.z CAR T-cells | SB | Recruiting | [71] |
| B-ALL, B-cell lymphoma, B-CLL | NCT03579888 | MDACC | Adult; Phase 1 | CD19.CD8.CD28.CD3.zCAR-mbIL15-HER1t T-cells | SB | Not yet recruiting | [58] |
| GBM 3, NSCLC 4, Breast Cancer, GI 5/GU 6, Ovarian Cancer |
NCT04102436 | NCI 11 (Maryland, USA) | Adult; Phase 2 | Autologous neoantigen-specific TCR T-cells | SB | Recruiting | [83] |
| Alzheimer’s Disease | NCT01163825 | KU 12 (Sweden) | Adult; Phase 1 | Encapsulated Cell Biodelivery of Nerve Growth Factor | SB | Unknown | [84] |
| MPS IH 7 | NCT04284254 | MCC 13 (USA) | Adult; Phase 1 and 2 | Autologous IDUA plasmablasts | SB | Not yet recruiting | |
| B-ALL, B-cell lymphoma, B-CLL | The CARTELL Study | WH, WHC, SCH 14 (Australia) | Children and adult; Phase 1 | Allogeneic anti-CD19 CAR T-cells | PB 17 | Recruiting | |
| B-ALL | UMIN000030984 | NUG 15 (Japan) | Children and adult; Phase 1 | Autologous anti-CD19 CAR T-cells | PB | Recruiting | |
| B-ALL, B-cell lymphoma | NCT04289220 | YAHKMU 16 (China) | Adult; Phase 1 | anti-CD19.CD28.41BB.z CAR T-cells | PB | Not yet recruiting |
1 B-ALL: B-Acute lymphoblastic leukemia; 2 B-CLL: B-Chronic lymphoblastic leukemia; 3 GBM: Glioblastoma; 4 NSCLC: Non-Small Cell Lung Cancer; 5 GI: Gastrointestinal Cancer; 6 GU: Genitourinary Cancer; 7 MPS IH: Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome); 8 MDACC: MD Anderson Cancer Center; 9 MBBM: Fondazione MBBM; 10 PGXXIII: ASST Papa Giovanni XXIII; 11 NCI: National Cancer Institute; 12 KU: Karolinska University Hospital; 13 MCC: Masonic Cancer Center, University of Minnesota; 14 WH, WHC, SCH: Westmead Hospital, Westmead Children’s Hospital, Sydney Children’s Hospital; 15 NUG: Nagoya University Graduate School of Medicine; 16 YAHKMU: Yan’an Affiliated Hospital of Kunming Medical University; 17 PB: piggyBac.